DexCom, Inc. (NASDAQ:DXCM) Stock Has Consensus Target Price of $92.43 According to Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned an average recommendation of “Buy” from the twenty-four research firms that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $92.43.

A number of research firms recently commented on DXCM. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Monday, August 3rd. Royal Bank Of Canada restated an “outperform” rating and issued a $105.00 price objective (up from $90.00) on shares of DexCom in a research report on Thursday, October 1st. BTIG Research upped their target price on DexCom from $90.00 to $96.00 and gave the company a “buy” rating in a report on Monday, October 12th. Truist Financial set a $102.00 price target on shares of DexCom and gave the company a “buy” rating in a report on Friday, September 18th. Finally, UBS Group set a $96.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Tuesday, July 28th.

Insider Buying and Selling

In other news, Director Mark G. Foletta sold 2,000 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the sale, the director directly owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This represents a 3.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the sale, the director directly owned 29,293 shares in the company, valued at $2,461,783.72. The trade was a 18.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,257 shares of company stock valued at $2,049,173 over the last 90 days. 0.28% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DexCom

A number of hedge funds have recently bought and sold shares of the company. Wedbush Securities Inc. raised its holdings in DexCom by 2.6% in the third quarter. Wedbush Securities Inc. now owns 15,286 shares of the medical device company’s stock worth $1,319,000 after buying an additional 383 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its stake in DexCom by 2.8% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock valued at $475,000 after acquiring an additional 150 shares during the period. Yousif Capital Management LLC lifted its stake in DexCom by 2.4% during the 3rd quarter. Yousif Capital Management LLC now owns 46,757 shares of the medical device company’s stock valued at $4,035,000 after acquiring an additional 1,099 shares during the period. Brookstone Capital Management boosted its holdings in shares of DexCom by 449.8% during the 3rd quarter. Brookstone Capital Management now owns 29,639 shares of the medical device company’s stock valued at $2,558,000 after acquiring an additional 24,248 shares during the last quarter. Finally, Root Financial Partners LLC purchased a new stake in shares of DexCom during the 3rd quarter valued at about $193,000. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $78.32 on Tuesday. The stock has a market cap of $29.55 billion, a PE ratio of 31.48, a PEG ratio of 1.34 and a beta of 1.48. The company’s fifty day moving average is $87.03 and its 200 day moving average is $76.53. DexCom has a 52 week low of $54.11 and a 52 week high of $92.59. The company has a quick ratio of 1.43, a current ratio of 1.73 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The company’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.48 earnings per share. Research analysts anticipate that DexCom will post 2.64 earnings per share for the current year.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.